Setting International Standards in
Analysing Patient-Reported Outcomes
and Quality of Life Endpoints


SISAQOL-IMI is led by the EORTC and Boehringer Ingelheim.

The management structure of SISAQOL-IMI consists of the General Assembly, the Steering Committee, the Project Coordination team, Independent Ethics Advisory Board (IEAB) and the Independent Scientific Advisory Board (ISAB).

SISAQOL-IMI is a public-private collaborative research project:

WP Public Lead EFPIA Lead
1 Madeline Pe, Ahu Alanya (EORTC) Anders Ingelgaard (Boehringer Ingelheim)
2 Corneel Coens (EORTC) Michael Schlichting (Merck KGaA)
3 Saskia le Cessie (Leiden University Medical Center) Satrajit Roychoudhury (Pfizer)
4 Bernhard Holzner (Medical University of Innsbruck) Jane Chang (Pfizer)
5 Martin Taphoorn (Leiden University Medical Center) Paul Cislo (Pfizer)
6 Johannes Giesinger (Medical University of Innsbruck) Jinma Ren (Pfizer)
7 Kristin Bjordal (Oslo University Hospital) Vivek Pawar (EMD Serono)
8 Silene ten Seldam (Myeloma Patients Europe) Elektra Papadopoulos (AbbVie)

Want to know more about SISAQOL-IMI?